10 most recent filings and news items mentioning GILD. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/GILD/news?limit=20"
Pull GILD filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayKathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
View filing at SEC.gov →Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
View filing at SEC.gov →Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill
View filing at SEC.gov →Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says
View filing at SEC.gov →Merck Announces FDA Approval Of KEYTRUDA And KEYTRUDA QLEX, Each In Combination With Trodelvy, For First-Line Treatment Of Breast Cancer
View filing at SEC.gov →Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer
View filing at SEC.gov →Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
View filing at SEC.gov →Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC
View filing at SEC.gov →Gilead And Merck Report Phase 3 Results For Once-Weekly Oral HIV Regimen Islatravir/Lenacapavir; Meets Week 48 Endpoints In ISLEND-1 And ISLEND-2 Trials
View filing at SEC.gov →Gilead Sciences filed an underwriting agreement to issue $3 billion in senior notes with maturities ranging from 2028 to 2034 at rates between 4.250% and 4.900%. The debt offering provides capital financing and reflects investor demand for the biopharmaceutical company's credit.
View filing at SEC.gov →